Organovo Holdings, Inc. (ONVO)
NASDAQ: ONVO · Real-Time Price · USD
0.369
-0.010 (-2.61%)
Feb 21, 2025, 4:00 PM EST - Market closed
Organovo Holdings Revenue
Organovo Holdings had revenue of $24.00K in the quarter ending December 31, 2024, with 380.00% growth. This brings the company's revenue in the last twelve months to $122.00K, down -49.59% year-over-year. In the fiscal year ending March 31, 2024, Organovo Holdings had annual revenue of $109.00K, down -70.54%.
Revenue (ttm)
$122.00K
Revenue Growth
-49.59%
P/S Ratio
45.95
Revenue / Employee
$6,100
Employees
20
Market Cap
5.67M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ONVO News
- 6 weeks ago - Organovo Announces Appointment of Norman Staskey as Chief Financial Officer - GlobeNewsWire
- 3 months ago - Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting - GlobeNewsWire
- 3 months ago - Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases - GlobeNewsWire
- 7 months ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July - Benzinga
- 7 months ago - Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis - GlobeNewsWire
- 9 months ago - Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease - GlobeNewsWire
- 10 months ago - Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) - GlobeNewsWire
- 10 months ago - Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering - GlobeNewsWire